SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mangalam Drugs receives final approval from WHO for Emtricitabine

16 Sep 2017 Evaluate

Mangalam Drugs & Organics has recently received the final approval from WHO for the drug Emtricitabine. Earlier in May, the company had received the final approval from WHO-Geneva for its plant at Unit-2 situated at G.I.D.C, Vapi, in the state of Gujarat.

Mangalam Drugs & Organics is a part of the MangalamGroup, manufactures chemicals such as API perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates at VAPI-Gujarat State. It has a multi-product manufacturing facility and a in-house Research and Development (R&D) Base.


Mangalam Drugs&Org. Share Price

29.23 0.00 (0.00%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.95
Dr. Reddys Lab 1242.75
Cipla 1230.00
Zydus Lifesciences 935.00
Lupin 2337.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×